1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Hepatitis C Drugs Market Size Growth Rate by Type: 2020 VS 2026 1.2.2 Anti-Viral 1.2.3 Immuno-modulators 1.2.4 Others 1.3 Market by Application 1.3.1 Global Hepatitis C Drugs Market Share by Application: 2020 VS 2026 1.3.2 Hospitals 1.3.3 Clinics 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Hepatitis C Drugs Market Perspective (2015-2026) 2.2 Global Hepatitis C Drugs Growth Trends by Regions 2.2.1 Hepatitis C Drugs Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Hepatitis C Drugs Historic Market Share by Regions (2015-2020) 2.2.3 Hepatitis C Drugs Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Hepatitis C Drugs Players by Market Size 3.1.1 Global Top Hepatitis C Drugs Players by Revenue (2015-2020) 3.1.2 Global Hepatitis C Drugs Revenue Market Share by Players (2015-2020) 3.2 Global Hepatitis C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Hepatitis C Drugs Revenue 3.4 Global Hepatitis C Drugs Market Concentration Ratio 3.4.1 Global Hepatitis C Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Hepatitis C Drugs Revenue in 2019 3.5 Key Players Hepatitis C Drugs Area Served 3.6 Key Players Hepatitis C Drugs Product Solution and Service 3.7 Date of Enter into Hepatitis C Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Hepatitis C Drugs Breakdown Data by Type (2015-2026) 4.1 Global Hepatitis C Drugs Historic Market Size by Type (2015-2020) 4.2 Global Hepatitis C Drugs Forecasted Market Size by Type (2021-2026) 5 Hepatitis C Drugs Breakdown Data by Application (2015-2026) 5.1 Global Hepatitis C Drugs Historic Market Size by Application (2015-2020) 5.2 Global Hepatitis C Drugs Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Hepatitis C Drugs Market Size (2015-2026) 6.2 North America Hepatitis C Drugs Market Size by Type (2015-2020) 6.3 North America Hepatitis C Drugs Market Size by Application (2015-2020) 6.4 North America Hepatitis C Drugs Market Size by Country (2015-2020) 6.4.1 United States 6.4.2 Canada 7 Europe 7.1 Europe Hepatitis C Drugs Market Size (2015-2026) 7.2 Europe Hepatitis C Drugs Market Size by Type (2015-2020) 7.3 Europe Hepatitis C Drugs Market Size by Application (2015-2020) 7.4 Europe Hepatitis C Drugs Market Size by Country (2015-2020) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 7.4.6 Nordic 7.4.7 Rest of Europe 8 China 8.1 China Hepatitis C Drugs Market Size (2015-2026) 8.2 China Hepatitis C Drugs Market Size by Type (2015-2020) 8.3 China Hepatitis C Drugs Market Size by Application (2015-2020) 8.4 China Hepatitis C Drugs Market Size by Region (2015-2020) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 Southeast Asia 8.4.5 India 8.4.6 Australia 8.4.7 Rest of Asia-Pacific 9 Japan 9.1 Japan Hepatitis C Drugs Market Size (2015-2026) 9.2 Japan Hepatitis C Drugs Market Size by Type (2015-2020) 9.3 Japan Hepatitis C Drugs Market Size by Application (2015-2020) 9.4 Japan Hepatitis C Drugs Market Size by Country (2015-2020) 9.4.1 Mexico 9.4.2 Brazil 10 Southeast Asia 10.1 Southeast Asia Hepatitis C Drugs Market Size (2015-2026) 10.2 Southeast Asia Hepatitis C Drugs Market Size by Type (2015-2020) 10.3 Southeast Asia Hepatitis C Drugs Market Size by Application (2015-2020) 10.4 Southeast Asia Hepatitis C Drugs Market Size by Country (2015-2020) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 UAE 10.4.4 Rest of Middle East & Africa 11 Key Players Profiles 11.1 Gilead sciences 11.1.1 Gilead sciences Company Details 11.1.2 Gilead sciences Business Overview 11.1.3 Gilead sciences Hepatitis C Drugs Introduction 11.1.4 Gilead sciences Revenue in Hepatitis C Drugs Business (2015-2020)) 11.1.5 Gilead sciences Recent Development 11.2 Abbvi 11.2.1 Abbvi Company Details 11.2.2 Abbvi Business Overview 11.2.3 Abbvi Hepatitis C Drugs Introduction 11.2.4 Abbvi Revenue in Hepatitis C Drugs Business (2015-2020) 11.2.5 Abbvi Recent Development 11.3 Johnson & Johnson 11.3.1 Johnson & Johnson Company Details 11.3.2 Johnson & Johnson Business Overview 11.3.3 Johnson & Johnson Hepatitis C Drugs Introduction 11.3.4 Johnson & Johnson Revenue in Hepatitis C Drugs Business (2015-2020) 11.3.5 Johnson & Johnson Recent Development 11.4 Merck 11.4.1 Merck Company Details 11.4.2 Merck Business Overview 11.4.3 Merck Hepatitis C Drugs Introduction 11.4.4 Merck Revenue in Hepatitis C Drugs Business (2015-2020) 11.4.5 Merck Recent Development 11.5 Glaxosmithkline 11.5.1 Glaxosmithkline Company Details 11.5.2 Glaxosmithkline Business Overview 11.5.3 Glaxosmithkline Hepatitis C Drugs Introduction 11.5.4 Glaxosmithkline Revenue in Hepatitis C Drugs Business (2015-2020) 11.5.5 Glaxosmithkline Recent Development 11.6 Novartis 11.6.1 Novartis Company Details 11.6.2 Novartis Business Overview 11.6.3 Novartis Hepatitis C Drugs Introduction 11.6.4 Novartis Revenue in Hepatitis C Drugs Business (2015-2020) 11.6.5 Novartis Recent Development 11.7 Bristol-Myers Squibb 11.7.1 Bristol-Myers Squibb Company Details 11.7.2 Bristol-Myers Squibb Business Overview 11.7.3 Bristol-Myers Squibb Hepatitis C Drugs Introduction 11.7.4 Bristol-Myers Squibb Revenue in Hepatitis C Drugs Business (2015-2020) 11.7.5 Bristol-Myers Squibb Recent Development 11.8 Roche 11.8.1 Roche Company Details 11.8.2 Roche Business Overview 11.8.3 Roche Hepatitis C Drugs Introduction 11.8.4 Roche Revenue in Hepatitis C Drugs Business (2015-2020) 11.8.5 Roche Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Hepatitis C Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 3. Key Players of Anti-Viral Table 4. Key Players of Immuno-modulators Table 5. Key Players of Others Table 6. Global Hepatitis C Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 7. Global Hepatitis C Drugs Market Size by Regions (US$ Million): 2020 VS 2026 Table 8. Global Hepatitis C Drugs Market Size by Regions (2015-2020) (US$ Million) Table 9. Global Hepatitis C Drugs Market Share by Regions (2015-2020) Table 10. Global Hepatitis C Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 11. Global Hepatitis C Drugs Market Share by Regions (2021-2026) Table 12. Hepatitis C Drugs Market Market Trends Table 13. Hepatitis C Drugs Market Drivers Table 14. Hepatitis C Drugs Market Challenges Table 15. Hepatitis C Drugs Market Restraints Table 16. Global Hepatitis C Drugs Revenue by Players (2015-2020) (US$ Million) Table 17. Global Hepatitis C Drugs Market Share by Players (2015-2020) Table 18. Global Top Hepatitis C Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatitis C Drugs as of 2019) Table 19. Global Hepatitis C Drugs by Players Market Concentration Ratio (CR5 and HHI) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Hepatitis C Drugs Product Solution and Service Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Hepatitis C Drugs Market Size by Type (2015-2020) (US$ Million) Table 24. Global Hepatitis C Drugs Market Size Share by Type (2015-2020) Table 25. Global Hepatitis C Drugs Revenue Market Share by Type (2021-2026) Table 26. Global Hepatitis C Drugs Market Size Share by Application (2015-2020) Table 27. Global Hepatitis C Drugs Market Size by Application (2015-2020) (US$ Million) Table 28. Global Hepatitis C Drugs Market Size Share by Application (2021-2026) Table 29. North America Hepatitis C Drugs Market Size by Type (2015-2020) (US$ Million) Table 30. North America Hepatitis C Drugs Market Share by Type (2015-2020) Table 31. North America Hepatitis C Drugs Market Size by Application (2015-2020) (US$ Million) Table 32. North America Hepatitis C Drugs Market Share by Application (2015-2020) Table 33. North America Hepatitis C Drugs Market Size by Country (US$ Million) (2015-2020) Table 34. North America Hepatitis C Drugs Market Share by Country (2015-2020) Table 35. Europe Hepatitis C Drugs Market Size by Type (2015-2020) (US$ Million) Table 36. Europe Hepatitis C Drugs Market Share by Type (2015-2020) Table 37. Europe Hepatitis C Drugs Market Size by Application (2015-2020) (US$ Million) Table 38. Europe Hepatitis C Drugs Market Share by Application (2015-2020) Table 39. Europe Hepatitis C Drugs Market Size by Country (US$ Million) (2015-2020) Table 40. Europe Hepatitis C Drugs Market Share by Country (2015-2020) Table 41. China Hepatitis C Drugs Market Size by Type (2015-2020) (US$ Million) Table 42. China Hepatitis C Drugs Market Share by Type (2015-2020) Table 43. China Hepatitis C Drugs Market Size by Application (2015-2020) (US$ Million) Table 44. China Hepatitis C Drugs Market Share by Application (2015-2020) Table 45. China Hepatitis C Drugs Market Size by Region (US$ Million) (2015-2020) Table 46. China Hepatitis C Drugs Market Share by Region (2015-2020) Table 47. Japan Hepatitis C Drugs Market Size by Type (2015-2020) (US$ Million) Table 48. Japan Hepatitis C Drugs Market Share by Type (2015-2020) Table 49. Japan Hepatitis C Drugs Market Size by Application (2015-2020) (US$ Million) Table 50. Japan Hepatitis C Drugs Market Share by Application (2015-2020) Table 51. Japan Hepatitis C Drugs Market Size by Country (US$ Million) (2015-2020) Table 52. Japan Hepatitis C Drugs Market Share by Country (2015-2020) Table 53. Southeast Asia Hepatitis C Drugs Market Size by Type (2015-2020) (US$ Million) Table 54. Southeast Asia Hepatitis C Drugs Market Share by Type (2015-2020) Table 55. Southeast Asia Hepatitis C Drugs Market Size by Application (2015-2020) (US$ Million) Table 56. Southeast Asia Hepatitis C Drugs Market Share by Application (2015-2020) Table 57. Southeast Asia Hepatitis C Drugs Market Size by Country (US$ Million) (2015-2020) Table 58. Southeast Asia Hepatitis C Drugs Market Share by Country (2015-2020) Table 59. Gilead sciences Company Details Table 60. Gilead sciences Business Overview Table 61. Gilead sciences Product Table 62. Gilead sciences Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 63. Gilead sciences Recent Development Table 64. Abbvi Company Details Table 65. Abbvi Business Overview Table 66. Abbvi Product Table 67. Abbvi Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 68. Abbvi Recent Development Table 69. Johnson & Johnson Company Details Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Product Table 72. Johnson & Johnson Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 73. Johnson & Johnson Recent Development Table 74. Merck Company Details Table 75. Merck Business Overview Table 76. Merck Product Table 77. Merck Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 78. Merck Recent Development Table 79. Glaxosmithkline Company Details Table 80. Glaxosmithkline Business Overview Table 81. Glaxosmithkline Product Table 82. Glaxosmithkline Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 83. Glaxosmithkline Recent Development Table 84. Novartis Company Details Table 85. Novartis Business Overview Table 86. Novartis Product Table 87. Novartis Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 88. Novartis Recent Development Table 89. Bristol-Myers Squibb Company Details Table 90. Bristol-Myers Squibb Business Overview Table 91. Bristol-Myers Squibb Product Table 92. Bristol-Myers Squibb Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 93. Bristol-Myers Squibb Recent Development Table 94. Roche Business Overview Table 95. Roche Product Table 96. Roche Company Details Table 97. Roche Revenue in Hepatitis C Drugs Business (2015-2020) (US$ Million) Table 98. Roche Recent Development Table 99. Research Programs/Design for This Report Table 100. Key Data Information from Secondary Sources Table 101. Key Data Information from Primary Sources List of Figures Figure 1. Global Hepatitis C Drugs Market Share by Type: 2020 VS 2026 Figure 2. Anti-Viral Features Figure 3. Immuno-modulators Features Figure 4. Others Features Figure 5. Global Hepatitis C Drugs Market Share by Application: 2020 VS 2026 Figure 6. Hospitals Case Studies Figure 7. Clinics Case Studies Figure 8. Hepatitis C Drugs Report Years Considered Figure 9. Global Hepatitis C Drugs Market Size (US$ Million), YoY Growth 2015-2026 Figure 10. Global Hepatitis C Drugs Market Share by Regions: 2020 VS 2026 Figure 11. Global Hepatitis C Drugs Market Share by Regions (2021-2026) Figure 12. Global Hepatitis C Drugs Market Share by Players in 2019 Figure 13. Global Top Hepatitis C Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatitis C Drugs as of 2019 Figure 14. The Top 10 and 5 Players Market Share by Hepatitis C Drugs Revenue in 2019 Figure 15. North America Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 16. United States Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 17. Canada Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 18. Europe Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 19. Germany Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 20. France Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 21. U.K. Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 22. Italy Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 23. Russia Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 24. Nordic Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 25. Rest of Europe Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 26. Asia-Pacific Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 27. China Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 28. Japan Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 29. South Korea Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 30. Southeast Asia Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 31. India Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 32. Australia Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 33. Rest of Asia-Pacific Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 34. Latin America Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 35. Mexico Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 36. Brazil Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 37. Middle East & Africa Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 38. Turkey Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 39. Saudi Arabia Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 40. UAE Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 41. Rest of Middle East & Africa Hepatitis C Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 42. Gilead sciences Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 43. Abbvi Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 44. Johnson & Johnson Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 45. Merck Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 46. Glaxosmithkline Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 47. Novartis Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 49. Roche Revenue Growth Rate in Hepatitis C Drugs Business (2015-2020) Figure 50. Bottom-up and Top-down Approaches for This Report Figure 51. Data Triangulation Figure 52. Key Executives Interviewed

Gilead sciences Abbvi Johnson & Johnson Merck Glaxosmithkline Novartis Bristol-Myers Squibb Roche